GUTS revenueFY2025$0
- FY YoY
- -100.0%
GUTS revenue was $0 for fiscal 2025 (ended Dec 31, 2025), down 100.0% from fiscal 2024.
Fractyl Health Inc. (GUTS) financials
For fiscal 2025 (ended Dec 31, 2025), Fractyl Health Inc. reported $0 of revenue and -$140.95M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$140.95M
- Free cash flow, FY2025
- -$90.89M
- EPS, diluted, FY2025
- -$1.86
- Cash
- $47.14M
- Market cap
- $11.9M
FY2023FY2025
FY2023FY2025
FY2023FY2025
GUTS revenue and earnings growth
GUTS net incomeQ2 2026-$25.54M
GUTS net income was -$25.54M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$27.89M a year earlier. For the full fiscal 2025 it was -$140.95M, compared with -$68.69M in fiscal 2024.
GUTS EPSQ2 2026-$0.16
GUTS diluted EPS was -$0.16 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.86.
GUTS free cash flowQ4 2025-$21.34M
GUTS free cash flow was -$21.34M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$17.27M a year earlier. For the full fiscal 2025 it was -$90.89M, compared with -$67.29M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $93.0K | $120.0K |
| Cost of revenue | $0 | $50.0K | $77.0K |
| Gross profit | $0 | $43.0K | $43.0K |
| Research and development | $74.54M | $70.47M | $38.04M |
| Selling, general and admin | $22.28M | $23.10M | $12.84M |
| Operating income | -$96.82M | -$93.53M | -$50.84M |
| Income tax | $0 | $0 | $0 |
| Net income | -$140.95M | -$68.69M | -$77.09M |
| EPS, basic | -$1.86 | -$1.62 | -$45.29 |
| EPS, diluted | -$1.86 | -$1.62 | -$45.29 |
| Diluted shares | 75.8M | 43.5M | 2.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $81.54M | $71.72M | $37.78M |
| Receivables | - | $0 | $22.0K |
| Inventory | - | $73.0K | $73.0K |
| Current assets | $87.58M | $71.76M | $35.65M |
| Total assets | $121.40M | $108.08M | $76.21M |
| Current liabilities | $18.33M | $19.77M | $11.19M |
| Long-term debt | - | - | $27.16M |
| Total debt | - | - | $27.16M |
| Total liabilities | $111.94M | $79.65M | $113.94M |
| Shareholders' equity | $9.46M | $28.42M | -$325.06M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$90.33M | -$65.52M | -$42.82M |
| Capital expenditures | $557.0K | $1.76M | $359.0K |
| Free cash flow | -$90.89M | -$67.29M | -$43.18M |
| Investing cash flow | -$557.0K | -$1.76M | -$359.0K |
| Financing cash flow | $104.96M | $101.23M | $27.44M |
| Stock-based compensation | $6.68M | $14.43M | $4.30M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | -100.0% | -22.5% | - |
| Gross margin | - | 46.2% | 35.8% |
| Operating margin | - | -100571.0% | -42363.3% |
| Net margin | - | -73864.5% | -64242.5% |
| Free cash flow margin | - | -72350.5% | -35985.0% |
| Return on equity | -1490.3% | -241.7% | - |
| Return on assets | -116.1% | -63.6% | -101.2% |
| Current ratio | 4.78 | 3.63 | 3.19 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $3.0K | $14.0K | $43.0K | $33.0K | $7.0K | $36.0K |
| Cost of revenue | - | - | - | - | - | - | $0 | $7.0K | $24.0K | $19.0K | $2.0K | $25.0K |
| Gross profit | - | - | - | - | - | - | $3.0K | $7.0K | $19.0K | $14.0K | $5.0K | $11.0K |
| Research and development | $13.81M | $15.60M | $16.49M | $17.46M | $21.15M | $19.43M | $20.28M | $19.00M | $16.76M | $14.42M | $10.17M | $9.38M |
| Selling, general and admin | $5.28M | $5.22M | $6.79M | $5.24M | $4.93M | $5.32M | $4.93M | $4.80M | $6.24M | $7.13M | $2.82M | $4.50M |
| Operating income | -$19.10M | -$20.82M | -$23.28M | -$22.69M | -$26.08M | -$24.76M | -$25.21M | -$23.79M | -$22.98M | -$21.54M | -$12.98M | -$13.87M |
| Net income | -$25.54M | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | -$24.97M | -$23.17M | -$17.23M | -$3.32M | -$19.18M | -$15.75M |
| EPS, basic | -$0.16 | $0.06 | - | -$0.71 | -$0.57 | -$0.49 | - | -$0.48 | -$0.36 | -$0.17 | -$11.19 | -$9.61 |
| EPS, diluted | -$0.16 | $0.06 | - | -$0.71 | -$0.57 | -$0.49 | - | -$0.48 | -$0.36 | -$0.17 | -$11.19 | -$9.61 |
| Diluted shares | 158.6M | 158.5M | - | 64.7M | 49.0M | 48.9M | - | 48.0M | 47.9M | 29.7M | - | 2.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $47.14M | $63.17M | $81.54M | $77.66M | $26.55M | $46.36M | $71.72M | $88.92M | $107.01M | $126.01M | $37.78M | $49.07M |
| Receivables | - | - | - | - | - | - | $0 | $0 | $22.0K | $15.0K | $22.0K | - |
| Inventory | - | - | - | - | - | - | $73.0K | $73.0K | $64.0K | $73.0K | $73.0K | - |
| Current assets | $49.60M | $65.92M | $87.58M | $79.70M | $26.69M | $47.05M | $71.76M | $87.65M | $106.56M | $124.47M | $35.65M | - |
| Total assets | $81.98M | $99.39M | $121.40M | $114.27M | $62.01M | $83.04M | $108.08M | $126.92M | $146.44M | $163.52M | $76.21M | - |
| Current liabilities | $15.74M | $15.41M | $18.33M | $18.68M | $21.83M | $18.80M | $19.77M | $15.72M | $14.28M | $13.27M | $11.19M | - |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | $27.16M | - |
| Total debt | - | - | - | - | - | - | - | - | - | - | $27.16M | - |
| Total liabilities | $83.64M | $78.01M | $111.94M | $117.45M | $80.22M | $76.67M | $79.65M | $76.60M | $75.68M | $79.34M | $113.94M | - |
| Shareholders' equity | -$1.67M | $21.38M | $9.46M | -$3.18M | -$18.21M | $6.38M | $28.42M | $50.32M | $70.75M | $84.18M | -$325.06M | -$307.18M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.90M | -$22.48M | -$21.34M | -$22.71M | -$21.20M | -$25.08M | -$17.03M | -$18.04M | -$18.74M | -$11.71M | -$10.60M | -$11.02M |
| Capital expenditures | - | - | $3.0K | $8.0K | $98.0K | $448.0K | $233.0K | $213.0K | $260.0K | $1.06M | $136.0K | $148.0K |
| Free cash flow | - | - | -$21.34M | -$22.72M | -$21.30M | -$25.53M | -$17.27M | -$18.25M | -$19.00M | -$12.77M | -$10.73M | -$11.17M |
| Investing cash flow | - | - | -$3.0K | -$8.0K | -$98.0K | -$448.0K | -$233.0K | -$213.0K | -$260.0K | -$1.06M | -$136.0K | -$148.0K |
| Financing cash flow | -$127.0K | $4.11M | $25.22M | $78.09M | $1.48M | $171.0K | $67.0K | $162.0K | -$5.0K | $101.00M | -$556.0K | $27.97M |
| Stock-based compensation | $2.50M | $2.53M | $1.85M | $1.64M | $1.78M | $1.41M | $2.90M | $2.52M | $3.79M | $5.22M | $1.28M | $1.09M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -57.1% | -61.1% | -40.3% | 560.0% | - | - |
| Gross margin | - | - | - | - | - | - | 100.0% | 50.0% | 44.2% | 42.4% | 71.4% | 30.6% |
| Operating margin | - | - | - | - | - | - | -840333.3% | -169957.1% | -53453.5% | -65278.8% | -185442.9% | -38536.1% |
| Net margin | - | - | - | - | - | - | -832333.3% | -165521.4% | -40067.4% | -10066.7% | -274000.0% | -43741.7% |
| Free cash flow margin | - | - | - | - | - | - | -575566.7% | -130371.4% | -44179.1% | -38697.0% | -153357.1% | -31016.7% |
| Current ratio | 3.15 | 4.28 | 4.78 | 4.27 | 1.22 | 2.50 | 3.63 | 5.58 | 7.46 | 9.38 | 3.19 | - |
Source: XBRL data Fractyl Health Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GUTS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GUTS | $0 | -100.0% | -$140.95M | - | $11.9M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
GUTS FAQ
8 questionsWhat is GUTS revenue?
Fractyl Health Inc. (GUTS) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is GUTS profitable?
No. Fractyl Health Inc. reported a net loss of $140.95M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does GUTS have?
Fractyl Health Inc. reported $47.14M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is GUTS revenue growing?
Fractyl Health Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is GUTS free cash flow?
Fractyl Health Inc. generated -$90.89M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$90.33M less capital expenditures.What is GUTS earnings per share?
Diluted earnings per share were -$1.86 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did GUTS last report financial results?
The latest statements here come from Fractyl Health Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this GUTS financial data come from?
Quantisnow builds these statements from the structured XBRL data Fractyl Health Inc. files with the SEC. It is provided for information only and is not investment advice.